198 related articles for article (PubMed ID: 33855091)
1. Downregulation of RIPK4 Expression Inhibits Epithelial-Mesenchymal Transition in Ovarian Cancer through IL-6.
Yi H; Su YZ; Lin R; Zheng XQ; Pan D; Lin DM; Gao X; Zhang R
J Immunol Res; 2021; 2021():8875450. PubMed ID: 33855091
[TBL] [Abstract][Full Text] [Related]
2. RIPK4 Promotes Cell Invasion and the Epithelial-Mesenchymal Transition in Ovarian Cancer.
Hua L; Wu JH; Xu JY; Wu SG; Zhou J
Front Biosci (Landmark Ed); 2023 Dec; 28(12):368. PubMed ID: 38179758
[TBL] [Abstract][Full Text] [Related]
3. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of RIPK4 Predicts Poor Prognosis and Promotes Metastasis in Ovarian Cancer.
Liu S; He L; Sheng C; Su R; Wu X; Sun Y; Xi X
Biomed Res Int; 2021; 2021():6622439. PubMed ID: 34124253
[TBL] [Abstract][Full Text] [Related]
5. Receptor interacting protein kinase 4 promotes cell proliferation, migration, and invasion in ovarian cancer via targeting protein kinase C delta.
Jin A; Zhang L; Fang G; Chen Y
Drug Dev Res; 2022 Apr; 83(2):407-415. PubMed ID: 34414590
[TBL] [Abstract][Full Text] [Related]
6. TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition.
Amoroso MR; Matassa DS; Agliarulo I; Avolio R; Lu H; Sisinni L; Lettini G; Gabra H; Landriscina M; Esposito F
Cell Death Dis; 2016 Dec; 7(12):e2522. PubMed ID: 27977010
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA miR-330-3p suppresses the progression of ovarian cancer by targeting RIPK4.
Cai L; Ye L; Hu X; He W; Zhuang D; Guo Q; Shu K; Jie Y
Bioengineered; 2021 Dec; 12(1):440-449. PubMed ID: 33487072
[TBL] [Abstract][Full Text] [Related]
8. RIPK4 Is an Immune Regulating-Associated Biomarker for Ovarian Cancer and Possesses Generalization Value in Pan-Cancer.
Liao C; Zhao YX; Han WD; Lai NY
J Immunol Res; 2022; 2022():7599098. PubMed ID: 35310605
[TBL] [Abstract][Full Text] [Related]
9. MiR-29c-3p, a target miRNA of LINC01296, accelerates tumor malignancy: therapeutic potential of a LINC01296/miR-29c-3p axis in ovarian cancer.
Xu H; Mao HL; Zhao XR; Li Y; Liu PS
J Ovarian Res; 2020 Mar; 13(1):31. PubMed ID: 32192508
[TBL] [Abstract][Full Text] [Related]
10. Silencing of RIPK4 inhibits epithelial‑mesenchymal transition by inactivating the Wnt/β‑catenin signaling pathway in osteosarcoma.
Yi Z; Pu Y; Gou R; Chen Y; Ren X; Liu W; Dong P
Mol Med Rep; 2020 Mar; 21(3):1154-1162. PubMed ID: 32016450
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of Tripartite Motif Containing 28 suppresses the migration, invasion and epithelial-mesenchymal transition in ovarian carcinoma cells through down-regulation of Wnt/β-catenin signaling pathway.
Deng B; Zhang S; Zhang Y; Miao Y; Meng X; Guo K
Neoplasma; 2017; 64(6):893-900. PubMed ID: 28895414
[TBL] [Abstract][Full Text] [Related]
12. SMAD3 inducing the transcription of STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
Shi Y; Zhang J; Liu M; Huang Y; Yin L
J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575
[TBL] [Abstract][Full Text] [Related]
13. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
Zeng XY; Xie H; Yuan J; Jiang XY; Yong JH; Zeng D; Dou YY; Xiao SS
Cancer Biol Ther; 2019; 20(7):956-966. PubMed ID: 31062668
[No Abstract] [Full Text] [Related]
14. Knockdown of enhancer of rudimentary homolog inhibits proliferation and metastasis in ovarian cancer by regulating epithelial-mesenchymal transition.
Zhang D; Chu YJ; Song KJ; Chen YL; Liu W; Lv T; Wang J; Zhao H; Ren YZ; Xu JX; Xia NN; Li HX; Yao Q
Biomed Pharmacother; 2020 May; 125():109974. PubMed ID: 32036222
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of SPINK13 Promotes Metastasis by Regulating uPA in Ovarian Cancer Cells.
Cai S; Zhang P; Dong S; Li L; Cai J; Xu M
Cell Physiol Biochem; 2018; 45(3):1061-1071. PubMed ID: 29439245
[TBL] [Abstract][Full Text] [Related]
17. SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer.
Gao T; Zhang X; Zhao J; Zhou F; Wang Y; Zhao Z; Xing J; Chen B; Li J; Liu S
Cancer Lett; 2020 Jan; 469():89-101. PubMed ID: 31639424
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of lncRNA FAM83H-AS1 in ovarian cancer.
Gong YB; Zou YF
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4656-4662. PubMed ID: 31210291
[TBL] [Abstract][Full Text] [Related]
19. CircRNA FGFR3 induces epithelial-mesenchymal transition of ovarian cancer by regulating miR-29a-3p/E2F1 axis.
Zhou J; Dong ZN; Qiu BQ; Hu M; Liang XQ; Dai X; Hong D; Sun YF
Aging (Albany NY); 2020 Jul; 12(14):14080-14091. PubMed ID: 32668414
[TBL] [Abstract][Full Text] [Related]
20. Alteration of epithelial-mesenchymal transition markers in human normal ovaries and neoplastic ovarian cancers.
Yi BR; Kim TH; Kim YS; Choi KC
Int J Oncol; 2015 Jan; 46(1):272-80. PubMed ID: 25310727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
